Skip to content Skip to navigation

Drug Design Lab

Virtual Drug Design

Drug design refers to the inventive process of creating new compounds and medications based on our knowledge of a biological target. Often, this biological target is a protein that may be inhibited to provide a therapeutic effect. A detailed understanding of a protein’s structure and function is often required in the design of novel inhibitors. The Mahajan laboratory utilizes virtual, or computer-aided, drug design methods to model new compounds that are complementary to a target protein’s shape and charge. These protein-inhibitor complexes are modeled on our lab’s parallel computing system and can be visualized in three-dimensions on 3D monitors, providing an in-depth view of these molecular interactions. Virtually-designed compounds are then synthesized in collaboration with Stanford’s Medicinal Chemistry Knowledge Center for testing in biochemical and cellular assays.

Drug Repositioning

The development of new drugs can cost upward of a billion dollars and take over a decade before the drug reaches the market. Drug repositioning makes use of existing drugs for the treatment of diseases where there are few therapeutic options. This approach can provide a safer alternative to the development of new compounds, since repurposed drugs are already FDA-approved, have proven bio-availabilities, and well-characterized side-effect profiles. To identify which drugs to reposition, our laboratory performs proteomic analyses of liquid biopsies (e.g. vitreous or aqueous humor) from diseased patients to identify drug targets and biomarkers. This approach allows for rapid, real-time repositioning of available drugs to patients with few therapeutic options. 

Projects

Structure-based drug design for inherited eye diseases.
Identifying available drugs to treat patients with rare diseases using proteomics.

News

Jun 19 2019 | Posted In: 20/20 Blog, Press
Palo Alto, CA - Vinit Mahajan M.D., Ph.D., Stanford vitreoretinal surgeon and Vice Chair of Research in the department of ophthalmology, was recently featured in the article, “
May 10 2019 | Posted In: 20/20 Blog
Menlo Park, CA — Gabe Valez, an M.D., Ph.D.
Feb 25 2019 | Posted In: 20/20 Blog
Palo Alto, CA —The Mahajan Lab in Stanford University’s Department of Ophthalmology is one of four 2018 recipients of the Stanford Alliance for Innovative Medicines (AIM) Grant.
Feb 4 2019 | Posted In: 20/20 Blog
Palo Alto, CA — How can physicians and scientists make clinical trials faster, cheaper, and more likely to succeed? The answer may be proteomic analysis.
Sep 26 2018 | Posted In: 20/20 Blog
Palo Alto, CA — Physicians, scientists, engineers, entrepreneurs, and patients are collaborating in an effort to move ophthalmology away from symptom-based, trial and error approaches to personalized treatment plans. 

Publications

Translation of CRISPR Genome Surgery to the Bedside for Retinal Diseases., Xu, Christine L., Cho Galaxy Y., Sengillo Jesse D., Park Karen S., Mahajan Vinit B., and Tsang Stephen H. , Front Cell Dev Biol, 2018, Volume 6, p.46, (2018)
Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers, Cabral, Thiago, Lima Luiz H., Mello Luiz Guilherme, Polido Júlia, Correa Éverton P., Oshima Akiyoshi, Duong Jimmy, Serracarbassa Pedro, Regatieri Caio V., Mahajan Vinit B., et al. , Ophthalmology Retina, Volume 2, p.31–37, (2018)
Personalized proteomics in proliferative vitreoretinopathy implicate hematopoietic cell recruitment and mTOR as a therapeutic target, C Roybal, Nathaniel, Velez Gabriel, Toral Marcus A., Tsang Stephen H., Bassuk Alexander G., and Mahajan Vinit B. , American journal of ophthalmology, (2017)
Retinal and choroidal angiogenesis: a review of new targets, Cabral, Thiago, Mello Luiz Guilherme, Lima Luiz H., Polido Júlia, Regatieri Caio V., Belfort Rubens, and Mahajan Vinit B. , International journal of retina and vitreous, Volume 3, Number 1, p.31, (2017)
Therapeutic drug repositioning using personalized proteomics of liquid biopsies, Velez, Gabriel, Bassuk Alexander G., Colgan Diana, Tsang Stephen H., and Mahajan Vinit B. , JCI insight, Volume 2, (2017)
Ocular hypertension after intravitreal dexamethasone (Ozurdex) sustained-release implant, Chin, Eric K., Almeida David R. P., Velez Gabriel, Xu Kunyong, Peraire Maria, Corbella Maria, Elshatory Yasser M., Kwon Young H., Gehrs Karen M., H Boldt Culver, et al. , Retina, Volume 37, p.1345–1351, (2017)